OSSDSIGN®

2026
Interim Report for the third quarter

January – September 2026



Interim Report for the third quarter of 2026

January 1 – September 30, 2026

The third quarter in figures

- Net sales amounted to TSEK 35,728 (44,020), which translates to an 8.2% decrease quarter-over-quarter with constant exchange rates, or 5.4% decrease in reported figures. This was in line with our expectations, as we commented during our Q2 release.
- Gross margin of 93.2% is an improvement over 92.1% in the previous quarter of 2026 but below 95.6% in the third quarter of the previous year. Some improvement in product and customer mix compared to the previous quarter.
- Adjusted EBIT of TSEK -6,615 (-5,319), with the reduction in operating expenses compensating for most of the gross profit shortfall.
- Reported EBIT of TSEK -6,863 (-5,533).
- Operating expenses were lower than last year with sales variable costs at 49.9% (48.7%) of net sales in the period.
- Net result for the period amounted to TSEK -5,776 (-5,781).
- Earnings per share of SEK -0.1 (-0.1).
- Cash flow from operating activities of TSEK –5,255 (-9,379), better than last year due to the favorable working capital development.

The first nine months in figures

- Net sales amounted to TSEK 110,383 (135,036), which translates to a 13.6% decrease with constant exchange rates, or 18.3% in reported figures.
- Gross margin of 92.3% (96.3%), negatively affected by product and customer mix.
- Adjusted EBIT of TSEK -31,979 (-17,086), as a direct consequence of the lower sales and gross margin, with some mitigation from the lower operating expenses.
- Reported EBIT of TSEK -32,677 (-25,167).
- Operating expenses were lower than last year and sales variable costs were down to 47.2% (48.9%) of net sales in the period.
- Net result for the period amounted to TSEK -28,658 (-28,699).
- Earnings per share of SEK -0.3 (-0.3).
- Cash flow from operating activities of TSEK -31,932 (-47,148), due to the favorable working capital development in the first nine months of 2026.

Significant events during the third quarter

- OssDsign surpasses 400 patients in PROPEL spine registry evaluating OssDsign Catalyst®.

Significant events after the end of the third quarter

- There were no significant events after the end of the third quarter.

Financial overview

	2026	2025	2026	2025	2025
The group	Jul 1 - Sep 30	Jul 1 - Sep 30	Jan 1 - Sep 30	Jan 1 – Sep 30	Jan 1 – Dec 31
Net sales, TSEK	35 728	44 020	110 383	135 036	180 159
Adjusted operating result, TSEK	-6 615	-5 319	-31 979	-17 086	-26 499
Operating result, TSEK	-6 863	-5 533	-32 677	-25 167	-46 757
Result for the period, TSEK	-5 776	-5 781	-28 658	-28 699	-50 988
Equity ratio, %	79%	81%	79%	81%	77%
Earnings per share, SEK	-0.1	-0.1	-0.3	-0.3	-0.5
Average number of employees	38.5	32.1	36.2	31.4	32.0



“We’ve launched the first guarantee of its kind among competitive products in the spine market.”

Focused on the levers for sales growth

In the third quarter, we made progress in several key areas as we continued to strengthen OssDsign’s foundation. We remain committed to returning to growth, driven by key levers: Expanding awareness and communications related to OssDsign Catalyst’s continued strong real-world performance, and the scaling of a more growth focused US commercial channel. Just before the quarter, we announced the appointment of a new Vice President of Sales in the US. Following this important hire, we have now also filled a key sales leadership role for our eastern territories, which had been vacant since May. As we commented previously, reshaping our sales organization is not only about quickly growing our team, but also about ensuring we maintain high standards. We are making good progress on both fronts.

Revenue for July through September 2026 totaled USD 3.7 million, or SEK 35.7 million, which was in line with our expectations. We fully anticipated, and commented on during our Q2 release, that customer holidays in the third quarter would soften our normal sales volumes. This materialized, but we still saw a solid finish to the quarter. OssDsign’s overall size has yet to reach a level where this kind of seasonality among certain customers has a negligible impact on our overall business. Year over year, revenue declined by 19.8% (-18.8% in SEK). Adjusted EBIT for the quarter was SEK -6.6 million, an improvement versus the -12.0 million reported in the second quarter. Gross margin also improved to 93.2%, versus 92.1% in Q2 2026. Although we have not yet returned to growth, we remain encouraged by some of our leading indicators. We’re also pleased to see those indicators within the context of ongoing disciplined capital allocation.

OssDsign Catalyst remains highly competitive, and this quarter we announced a significant milestone of over 400 patients enrolled in our Propel registry. High-quality, CT-verified fusion data from that registry was recently utilized to prepare and submit a significant labeling change for Catalyst. Additionally, we’ve now finalized our proposed level one study protocol, and we’re actively vetting potential interested sites. We will have more to say on the specific timing of first patient implantation soon.

During the quarter, we exhibited OssDsign Catalyst at seven surgeon society meetings. Immediately after the quarter closed, we also met with numerous surgeons at the North American Spine Society annual meeting in San Antonio, Texas. We ran a strong branding and awareness campaign both before and during the meeting, and OssDsign Catalyst’s impressive fusion rates in real-world, challenging patient populations drew significant attention.

We’ve mentioned before that each new clinical or scientific publication we release strengthens our position and supports our efforts to expand surgeon awareness and adoption. We’re working on the next Propel registry data release and expect that to happen in the first quarter of 2027. Because our observed performance of OssDsign Catalyst has been so consistently strong, even when used in challenging patient populations, we’ve launched the first guarantee of its kind among competitive products in the spine market. You can read more about the OssDsign Catalyst Commitment in our subsequent press release.

OssDsign remains laser-focused on the levers that support our short- and long-term growth, and we look forward to continuing to share our progress transparently as we execute our strategy for value creation.

Mark Waugh, CEO

Statement of Operations

OssDsign is a developer and provider of next generation orthobiologic products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities, giving patients back the life they deserve.

OssDsign Catalyst –
a state of the art nanosynthetic™ bone graft

Nearly 80% of Americans experience low back pain at some point in their lives and more than 1.5 million undergo spinal surgery each year, of which approximately half will need fusion surgery. Today approximately 20% of these surgeries are unsuccessful due to the lack of proper fusion (non-union). Bone graft plays a crucial role in the surgery to stimulate bone growth. The major advances provided by orthobiologic products are resulting in a shift in spinal surgery, as the use of synthetic bone graft substitutes has become more common to avoid the need to utilise allograft or iliac crest autograft.

Traditional synthetic materials share similarities with bone tissue at a macro level, rather than on a nano level, leading to a less effective bone formation response. OssDsign Catalyst is a latest-generation state of the art nanosynthetic™ bone graft composed of a proprietary nano-crystalline silicate calcium phosphate. Being similar to the body's own bone mineral architecture, OssDsign Catalyst provides a favorable bone biology environment for rapid and reliable bone formation.

Clear commercial advantages

OssDsign Catalyst is a high gross margin product with great scalability and large potential in the market for standard procedures, enabling extensive growth. OssDsign Catalyst received FDA clearance in 2020 and has been very well received in the U.S. market since its launch in August 2021. By the end of June 2026, more than 15,000 patients had been treated with OssDsign Catalyst in the U.S.

Improved patient outcomes

OssDsign Catalyst received FDA clearance in 2020 based on preclinical results from the most established and demanding non- clinical model for spinal fusion – the Boden model. OssDsign Catalyst surpasses results typically seen with other synthetic bone grafts used in this model.

This has also been confirmed in the clinical study TOP FUSION where top-line results show a 93% spinal fusion rate at 12 months after surgery and 100% at 24 months after surgery with the novel nanosynthetic™ bone graft. All scores used to quantify pain, function and overall health in patients showed improvement in quality of life over time and no device-related adverse events were observed during the study. This is also in line with the first post-market safety report that was published in November 2022, which did not record any device-related complaints or adverse events.

The data indicates that the use of OssDsign Catalyst leads to consistent and rapid bone healing and remodeling, with improved patient outcomes as a result. Altogether, OssDsign Catalyst has the proven potential to improve the success rates of spinal surgeries – a much-welcomed development for the millions of patients who require a spinal fusion to regain an active and healthy life.

Subsequently, the positive findings outlined here have been further corroborated by additional preclinical research, published in the Journal of Orthopaedic Surgery and Research, as well as clinically, from the first 108 patient readout from our PROPEL registry, showing an 88.4% fusion rate in a highly complex patient cohort.

USD 1.8 billion

The U.S. market value for orthobiologics in spinal surgeries.

Development of profit and financial position

THIRD QUARTER

Sales and Gross margin

The OssDsign Group net sales for the third quarter amounted to TSEK 35,728 (44,020), which translates to an 8.2% decrease quarter-over-quarter with constant exchange rates, or 5.4% decrease in reported figures. This was in line with our expectations, as we commented during our Q2 release. Compared to the third quarter of 2025, this translates to a decrease of 19.8% at constant exchange rates, or 18.8% in reported figures. The summer vacation effect was more pronounced this year, especially early in the period, followed by an improved sales trajectory throughout the quarter.

Gross margin of 93.2% is an improvement over 92.1% in the previous quarter of 2026 but below 95.6% in the third quarter of the previous year. Some improvement in product and customer mix compared to the previous quarter.

Operating result

Adjusted operating result of TSEK -6,615 (-5,319), with the reduction in operating expenses compensating for most of the gross profit shortfall. The effects of exchange rate changes at the EBIT level were marginal, due to the nature of our cost base, with the impact on operating expenses offsetting the effect on sales and COGS.

Total operating expenses, both sales variable and non-variable costs, were significantly lower than in the corresponding period in the previous year. Total operating expenses were also significantly lower than in the previous quarter of 2026. The lower level of operating expenses in the quarter was driven predominantly by seasonal factors, such as the vacation period, with a generally lower activity level, and an increased internal development project focus of resources.

Cash flow, investments and financial position

Cash at the beginning of the period amounted to TSEK 152,531 and at the end of the period TSEK 138,055. Cash flow from operating activities of TSEK –5,255 (-9,379) was better than last year due to the favourable working capital development. The positive working capital development was partly driven by the lower sales, generating lower receivables, but also from reduced inventory build-up, as adequate stock levels have now been reached.

Cash flow from investments of TSEK -9,648 (-1,690) was higher than previous quarters in 2026 and significantly higher than the third quarter in 2025, demonstrating the product development ramp-up as communicated in our strategic plan.

Total cash flow for the period was TSEK -14,780 (-1,745), with the deviation compared to the previous year largely driven by exercise of warrants from the 2022/25 program. There were no investments in tangible fixed assets in the period whereas new product development costs were capitalized to the amount of TSEK 9,648 (1,690) in intangible assets in the period.

FIRST NINE MONTHS

Sales and Gross margin

The OssDsign Group net sales for the first nine months of 2026 amounted to TSEK 110,383 (135,036), which translates to a 13.6% decrease compared to the first nine months of 2025 with constant exchange rates, or 18.3% in reported figures. The USD decline that started earlier this year has subsequently flattened out and turned around, thus closing the gap of the USD/SEK exchange rate impact on year-to-date numbers.

Gross margin of 92.3% (96.3%), was still negatively affected by product and customer mix companred to the corresponding period in the previous year.

Operating result

The adjusted operating result for the period January - September 2026 amounted to TSEK -31,979 (-17,086), as a direct consequence of the lower sales and gross margin, with some mitigation from the lower operating expenses. The effects of exchange rate changes at the EBIT level were marginal, due to the nature of our cost base, with the impact on operating expenses offsetting the effect on sales and COGS.

Total operating expenses, both sales variable and non-variable costs, were significantly lower than in the corresponding period in the previous year, with sales variable costs down to 47.2% (48.9%) of net sales in the period.

Cash flow, investments and financial position

Cash at the beginning of the period amounted to TSEK 100,858 and at the end of the period TSEK 138,055. Cash flow from operating activities amounted to TSEK -31,932 (-47,148), due to the favourable working capital development in the first nine months of 2026, but also to the comparison period being more heavily impacted by LTIP/warrant related costs.

Cash flow from investments of TSEK -21,807 (-4,922) was significantly higher than in the previous year, driven entirely by investments in new product development, as per our communicated strategic plan.

Total cash flow for the period was TSEK -53,902 (111,108), with the significant variance being driven by the directed share issue in the comparison period. There were no investments in tangible fixed assets in the period, with TSEK -677 of production related investments in the comparison period. New product development costs were capitalized to the amount of TSEK 21,807 (4,245) in intangible assets in the period.

SIGNIFICANT EVENTS DURING THE THIRD QUARTER

OssDsign surpasses 400 patients in PROPEL spine registry evaluating OssDsign Catalyst®

On September 9, OssDsign announced that more than 400 patients have been enrolled in the PROPEL registry, a prospective, multi-center, spine fusion registry evaluating its flagship product OssDsign Catalyst. The registry, that was initiated in March 2022, has previously demonstrated a fusion rate of 88.4% among the first 108 patients at 12 months across a highly complex patient cohort, proving its exceptional performance in spinal fusion surgery.

SIGNIFICANT EVENTS AFTER THE END OF THE THIRD QUARTER

There were no significant events after the end of the third quarter.



OTHER DISCLOSURES

Ownership structure

Owners	Number of shares	Share Capital, %
Försäkringsaktiebolaget Avanza Pension	13 367 802	12.1%
Linc AB	13 204 396	11.9%
TAMT AB	9 280 000	8.4%
FSG Fund	8 000 000	7.2%
SIX SIS AG, W8IMY	5 567 170	5.0%
Nordea Livförsäkring Sverige AB	4 461 801	4.0%
Protean Funds	3 181 369	2.9%
AGB KRONOLUND AKTIEBOLAG	3 150 000	2.8%
OLAUSSON THOMAS	2 410 000	2.2%
Nordnet Pensionsförsäkring AB	2 220 231	2.0%
Other shareholders	45 783 144	41.4%
Total	**110 625 913**	**100.00%**

Group structure

OssDsign AB is the parent company of the Group which, in addition to OssDsign AB, consists of the wholly owned subsidiaries OssDsign Ltd with its registered office in England, OssDsign USA Inc with its registered office in Maryland, USA, and Sirakoss Ltd with its registered office in Scotland. OssDsign's operations are mainly conducted through the parent company OssDsign AB, based in Uppsala, with the sales activities being conducted solely through OssDsign USA Inc.

Employees

At the end of the period, there were a total of 38 (32) employees, of whom 37% were women. This includes employees in Sweden, the U.K. and the U.S.

Financing

The Board regularly reviews the company's existing and forecasted cash flows to ensure that the company has the funds and resources required to conduct the business and the strategic direction decided by the Board. The company's long-term cash requirements are largely determined by how successful current and future products will be on the market. In order to satisfy requirements in the medium to long term, the company raised SEK 158 million in gross proceeds through a directed share issue in 2025. As of September 30, 2026, the group's cash and cash equivalents amounted to SEK 138.1 million. Based on the sales development of the company's products, the board has confidence in the company's mid- to long-term ability to become profitable and cash flow positive.

Transactions with related parties

The subsidiaries OssDsign USA Inc, OssDsign Ltd and Sirakoss Ltd invoice their costs to the parent company in accordance with transfer pricing agreements.

As of the closing date, the Parent Company has a claim on OssDsign USA Inc of TSEK 9,202 and a liability to Sirakoss Ltd of TSEK 1,875.

Risks and uncertainties

OssDsign risks and uncertainties include, but are not limited to, financial risks such as future financing, foreign exchange and credit risks. In addition to market risks, there are risks related to OssDsign operations, such as obtaining the necessary government licenses, product development, patents and intellectually property rights, product liability and forward-looking information that may affect the Company.

In addition, developments in recent years have also introduced war, inflation, energy cost increases, interest rate risks, trade barriers and global instability to the agenda, all of which may come to affect access to raw materials, distribution, cost of goods and services, as well as customer demand and access to capital. Further information regarding the Company's risk exposure can be found on pages 36-37 and 78-81 of the OssDsign Annual Report 2025.

The direction towards protectionism expressed by the U.S. administration can conceivably affect OssDsign's operations going forward. The US import tariffs, as communicated to date, however, are not deemed to have any material impact on the Group's future earnings or financial position.

Parent company

In the third quarter of 2026, the parent company's Net sales amounted to TSEK 3,977 (6,265). As all end customer sales are made from OssDsign USA Inc, the parent company sales are entirely intra-group.

The parent company's EBIT for the third quarter 2026 amounted to TSEK -16,630 (-9,744).

At the end of the period, there were a total of 3 (4) employees in the parent company, of whom 67% were women. This includes only employees in Sweden.

Condensed consolidated income statement

SEK 000'	2026 Jul 1 – Sep 30	2025 Jul 1 – Sep 30	2026 Jan 1 – Sep 30	2025 Jan 1 – Sep 30	2025 Jan 1 – Dec 31
Net sales	35 728	44 020	110 383	135 036	180 159
Cost of sales	-2 443	-1 948	-8 513	-5 042	-6 691
Gross profit	**33 286**	**42 073**	**101 870**	**129 994**	**173 468**
Sales commissions and fees	-17 826	-21 420	-52 121	-65 989	-87 484
Selling expenses	-9 655	-11 331	-39 191	-34 515	-47 874
R&D expenses	-3 474	-4 135	-10 606	-15 674	-20 118
Administrative expenses	-8 603	-10 767	-31 422	-39 216	-66 350
Other operating expense	-591	47	-1 208	234	1 603
Operating result	**-6 864**	**-5 534**	**-32 678**	**-25 168**	**-46 757**
Net financial items	1 203	-16	4 713	-2 942	-3 397
Result before income tax	**-5 661**	**-5 551**	**-27 964**	**-28 110**	**-50 154**
Income tax	-116	-231	-695	-590	-835
RESULT FOR THE PERIOD	**-5 777**	**-5 782**	**-28 659**	**-28 700**	**-50 988**

Condensed consolidated statement of comprehensive income

SEK 000'	2026 Jul 1 – Sep 30	2025 Jul 1 – Sep 30	2026 Jan 1 – Sep 30	2025 Jan 1 – Sep 30	2025 Jan 1 – Dec 31
Profit/loss for the period	-5 777	-5 782	-28 659	-28 700	-50 988
Items that will be reclassified subsequently to profit or loss	412	-214	940	-2 188	-17 379
Other comprehensive income for the period	412	-214	940	-2 188	-17 379
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	**-5 365**	**-5 996**	**-27 719**	**-30 888**	**-68 367**

Condensed consolidated balance sheet

SEK 000'	2026 Sep 30	2025 Sep 30	2025 Dec 31
ASSETS			
Fixed assets			
Intangible assets	169 758	163 077	150 029
Tangible fixed assets	1 192	2 218	1 906
Financial assets	2 700	135	132
Total fixed assets	**173 649**	**165 430**	**152 067**
Current assets			
Inventories	20 797	21 936	22 678
Accounts receivable	20 040	24 686	26 131
Tax receivable	9	541	–
Other receivables	367	435	590
Prepayments	5 334	6 819	5 061
Cash and cash equivalents	138 055	210 860	191 346
Total current assets	**184 602**	**265 277**	**245 806**
TOTAL ASSETS	**358 251**	**430 707**	**397 873**

SEK 000'	2026 Sep 30	2025 Sep 30	2025 Dec 31
SHAREHOLDER EQUITY AND LIABILITIES			
Equity	282 888	347 273	310 031
Total equity	**282 888**	**347 273**	**310 031**
Long-term liabilities			
Finance lease liabilities	–	663	403
Other liabilities	51 790	57 189	52 172
Total long-term liabilities	**51 790**	**57 852**	**52 575**
Current liabilities			
Accounts payable	4 874	4 519	5 327
Lease liabilities	698	977	969
Tax liability	–	–	48
Other current liabilities	479	968	10 002
Accrued expenses and deferred income	17 522	19 117	18 922
Total current liabilities	**23 573**	**25 582**	**35 268**
Total liabilities	**75 363**	**83 434**	**87 843**
TOTAL EQUITY AND LIABILITIES	**358 251**	**430 707**	**397 873**

Condensed consolidated change in shareholder's equity

SEK 000'	Share Capital	Other Capital Contributions	Reserves	Profit (loss) brought forward	Total Equity
Opening balance 2025-01-01	6 104	796 025	30 843	-618 909	214 061
Profit/loss for the period	–	–	–	-28 700	-28 700
Other comprehensive income	–	–	-2 188	–	-2 188
Total comprehensive income	**–**	**–**	**-2 188**	**-28 700**	**-30 888**
Transactions with shareholders					
Warrant program	–	–	–	5 094	5 094
New share issue	799	167 092	–	–	167 891
Issue expenses	–	-8 886	–	–	-8 886
Total transactions with shareholders	799	158 206	–	5 094	164 099
CLOSING BALANCE 2025-09-30	6 903	954 231	28 655	-642 515	347 273
Opening balance 2026-01-01	6 914	954 366	13 464	-664 711	310 031
Profit/loss for the period	–	–	–	-28 659	-28 659
Other comprehensive income	–	–	940	–	940
Total comprehensive income	**–**	**–**	**940**	**-28 659**	**-27 719**
Transactions with shareholders					
Warrant programmes	–	–	–	576	576
Total transactions with shareholders	–	–	–	576	576
CLOSING BALANCE 2026-09-30	6 914	954 366	14 404	-692 794	282 888

Condensed consolidated statement of cash flow

	2026	2025	2026	2025	2025
SEK 000'	Jul 1 - Sep 30	Jul 1 - Sep 30	Jan 1 – Sep 30	Jan 1 – Sep 30	Jan 1 – Dec 31
Operating activities					
Operating result	-6 864	-5 534	-32 678	-25 168	-46 757
Non cash adjustment	908	1 013	451	2 878	-788
Financial items	1 203	-16	4 713	-2 942	-3 397
Income taxes paid/received	-361	-321	-1 124	-1 342	-1 393
	-5 114	**-4 859**	**-28 638**	**-26 575**	**-52 335**
Changes in inventories	653	-4 013	2 446	-9 306	-10 182
Changes in receivables	3 815	-256	7 749	-5 747	-6 243
Changes in current liabilities	-4 609	-252	-13 488	-5 521	4 725
Total change in working capital	**-141**	**-4 520**	**-3 294**	**-20 574**	**-11 699**
Cash flow from operating activities	**-5 255**	**-9 379**	**-31 932**	**-47 148**	**-64 034**
Investment activities					
Proceeds and purchase of intangible assets, net	-9 648	-1 461	-21 807	-4 245	-6 723
Proceeds and purchase of property, plant and equipment, net	–	-229	–	-677	-677
Cash flow from investment activities	**-9 648**	**-1 690**	**-21 807**	**-4 922**	**-7 400**
Financing activities					
New share issue	–	9 767	–	167 892	168 086
Share issue costs	–	-318	–	-8 886	-8 934
Warrants	378	114	576	5 094	5 185
Proceeds/repayments from borrowings, net	–	–	–	-214	-214
Repayment of lease liabilities	-255	-239	-738	-708	-945
Cash flow from financing activities	**123**	**9 324**	**-162**	**163 178**	**163 178**
Cash flow for the period	**-14 780**	**-1 745**	**-53 902**	**111 108**	**91 743**
Cash and cash equivalents at the beginning of the period	152 531	212 739	191 346	100 858	100 858
Exchange rate adjustments – cash, cash equivalents and overdrafts	303	-133	610	-1 106	-1 255
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	**138 055**	**210 860**	**138 055**	**210 860**	**191 346**

Condensed income statement, parent company

SEK 000'	2026 Jul 1 – Sep 30	2025 Jul 1 – Sep 30	2026 Jan 1 – Sep 30	2025 Jan 1 – Sep 30	2025 Jan 1 – Dec 31
Net sales	3 977	6 265	16 838	22 754	25 023
Cost of goods sold	-2 686	-2 968	-10 104	-10 665	-11 389
Gross profit	**1 291**	**3 297**	**6 734**	**12 089**	**13 633**
Sales commissions and fees	-6	-1 091	-426	-2 546	-2 695
Selling expenses	-4 509	-250	-17 578	-581	-1 041
R&D expenses	-6 633	-4 853	-22 236	-15 098	-20 357
Administrative expenses	-6 773	-6 847	-22 008	-28 550	-47 812
Other operating expense	–	–	–	–	1 353
Operating result	**-16 630**	**-9 744**	**-55 514**	**-34 686**	**-56 919**
Net financial items	1 181	-14	4 697	-2 934	-3 390
Result before income tax	**-15 449**	**-9 758**	**-50 816**	**-37 620**	**-60 309**
Income tax	–	–	–	–	–
RESULT FOR THE PERIOD	**-15 449**	**-9 758**	**-50 816**	**-37 620**	**-60 309**

Condensed consolidated statement of comprehensive income, parent company

SEK 000'	2026 Jul 1 – Sep 30	2025 Jul 1 – Sep 30	2026 Jan 1 – Sep 30	2025 Jan 1 – Sep 30	2025 Jan 1 – Dec 31
Profit/loss for the period	-15 449	-9 758	-50 816	-37 620	-60 309
Items that will be reclassified subsequently to profit or loss	–	–	–	–	–
Other comprehensive income for the period	–	–	–	–	–
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	**-15 449**	**-9 758**	**-50 816**	**-37 620**	**-60 309**

Condensed balance sheet, parent company

SEK 000'	2026 Sep 30	2025 Sep 30	2025 Dec 31
ASSETS			
Fixed assets			
Financial assets	137 750	137 687	137 687
Total fixed assets	**137 750**	**137 687**	**137 687**
Current assets			
Inventories	17 723	18 367	20 563
Intercompany receivables	15 562	17 706	14 032
Tax receivable	671	670	363
Other receivables	228	310	468
Prepayments	2 091	2 274	1 989
Cash and cash equivalents	127 367	199 523	182 351
Total current assets	**163 643**	**238 850**	**219 765**
TOTAL ASSETS	**301 393**	**376 537**	**357 452**

SEK 000'	2026 Sep 30	2025 Sep 30	2025 Dec 31
SHAREHOLDER EQUITY AND LIABILITIES			
Equity			
Equity	236 474	309 675	287 132
Total equity	**236 474**	**309 675**	**287 132**
Provisions			
Other provisions	50 072	54 701	50 072
Total provisions	**50 072**	**54 701**	**50 072**
Current liabilities			
Accounts payable	2 409	2 926	2 579
Intercompany liabilities	8 235	1 527	1 838
Other current liabilities	189	408	9 780
Accrued expenses and deferred income	4 014	7 300	6 052
Total current liabilities	**14 847**	**12 162**	**20 249**
Total liabilities	**64 919**	**66 863**	**70 321**
TOTAL EQUITY AND LIABILITIES	**301 393**	**376 537**	**357 452**

Notes

Note 1 | Accounting Principles

This summary interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and applicable regulations in the Swedish Annual Accounts Act. The interim report for the Parent Company has been prepared in accordance with the Swedish Annual Accounts Act chapter 9, Interim Financial Reporting. The same accounting and valuation policies have been applied for the Group and the Parent Company as in the latest Annual Report. Disclosures in accordance with IAS 34.16A occur in the financial reports and the accompanying notes, and also in other parts of the interim report.

An alternative performance measure, Adjusted operating result (EBIT), was added in 2025. Adjusted EBIT is defined as EBIT excluding LTIP and CEO transition related costs.

ADJUSTED OPERATING RESULT

	Jul – Sep		Jan – Sep		Jan – Dec
SEK 000'	2026	2025	2026	2025	2025
EBIT	**-6 863**	**-5 533**	**-32 677**	**-25 167**	**-46 757**
LTIP related costs	248	214	698	8 081	8 172
CEO transition costs	–	–	–	–	12 086
Adjusted EBIT	**-6 615**	**-5 319**	**-31 979**	**-17 086**	**-26 499**

Note 2 | Estimates and assessments

Estimates and assessments are evaluated on an ongoing basis and are based on historical experience and other factors, including expectations of future events that are considered reasonable under prevailing conditions. There has been no change in the estimates and judgments made in the Annual Report for 2025.

Note 3 | Information regarding operating segments

The Group's operations are divided into operating segments based on the parts of the business the Company's highest executive decision-maker follows up, so called "management approach". The Group's internal reporting is based on the Group management following up the operation as a whole. Based on its internal reporting, the Group has identified that the Group has only one segment.

NET SALES BY GEOGRAPHIC MARKET

	Jul – Sep		Jan – Sep		Jan – Dec
SEK 000'	2026	2025	2026	2025	2025
USA	35 728	44 020	110 383	135 036	180 159
TOTAL	**35 728**	**44 020**	**110 383**	**135 036**	**180 159**

Income from external customers has been attributed to individual countries from which the sales have taken place. As of January 1, 2024, the only country in which such sales are taking place is the USA and only within the product category Orthobiologics. The Group's fixed assets are located to Sweden, the U.K. and the U.S.

NET SALES BY PRODUCT CATEGORY

	Jul – Sep		Jan – Sep		Jan – Dec
SEK 000'	2026	2025	2026	2025	2025
Orthobiologics	35 728	44 020	110 383	135 036	180 159
TOTAL	**35 728**	**44 020**	**110 383**	**135 036**	**180 159**

Note 4 | Equity

The share capital of the Parent Company consists only of fully paid ordinary shares with a nominal (quota value) value of SEK 0.0625 / share. The company has 110 625 913 class A shares.

	2026	2025
	Jan 1 – Sep 30	Jan 1 – Sep 30
Subscribed and paid shares		
At the beginning of the period	110 625 913	97 658 920
Directed share issue	–	11 500 000
Shares from exercise of warrant program	–	1 295 771
Subscribed and paid shares	**110 625 913**	**110 454 691**
Shares for share-based payments	–	–
SUM AT THE END OF THE PERIOD	**110 625 913**	**110 454 691**

Amounts received for issued shares in addition to the nominal value during the year (premium) are included in the item "Other contributed capital", after deduction for registration and other similar fees and after deduction for attributable tax benefits.

Signatures

The Board of Directors and the CEO provide their assurance that this interim report provides an accurate view of the operations, position and earning of the Group and the Parent Company, and that it also describes the principal risks and uncertainties faced by the Parent Company and the companies included within the Group.

This report has been prepared in both a Swedish and an English version. In the event of any discrepancy between the two, the Swedish version shall apply. This report has not been audited.

Financial calendar 2026

Year-end Report, 2026	February 16, 2027

OSSDSIGN AB – UPPSALA, NOVEMBER 3, 2026

Per Aniansson
Chairman of the Board

Jill Schiaparelli
Board member

Christer Fåhraeus
Board member

David Jern
Board member

Tomas Blomquist
Board member

Mark Waugh
CEO



OSSDSIGN®

OssDsign AB, Ulls väg 29C, SE 756 51 Uppsala, Sweden
info@ossdsign.com
ossdsign.com



CONTACT
Mark Waugh, CEO
+1 260-804-1342
mark.waugh@ossdsign.com

Anders Svensson, CFO
+46 (0) 70-272 96 40
anders.svensson@ossdsign.com